Investigational drug · Phase 2
REGN22530
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "REGN22530"
First trial start
2026
Sep 8, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "REGN22530", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Open Angle Glaucoma (POAG)
- Ocular Hypertension (OHT)
Approved drugs for the same conditions: High blood pressure (hypertension) · Glaucoma · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "REGN22530" as an intervention, largest first.
- REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular HypertensionPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07675824 · 271 participants (planned) · Start Sep 8, 2026 · Primary completion Sep 14, 2029
Drug: REGN22530 · For: Primary Open Angle Glaucoma (POAG); Ocular Hypertension (OHT)
Sites: Deerfield Beach, Florida
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Regeneron.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.